Compare AVB & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVB | GEHC |
|---|---|---|
| Founded | 1978 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Computer Software: Prepackaged Software |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 27.9B |
| IPO Year | 1995 | 2022 |
| Metric | AVB | GEHC |
|---|---|---|
| Price | $187.55 | $71.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $198.40 | $88.38 |
| AVG Volume (30 Days) | 708.4K | ★ 5.5M |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.86% | 0.24% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | ★ 3.43 | 0.85 |
| Revenue | $3,040,725,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $4.04 | $7.12 |
| Revenue Next Year | $5.03 | $4.45 |
| P/E Ratio | ★ $54.39 | $82.72 |
| Revenue Growth | 4.36 | ★ 4.84 |
| 52 Week Low | $160.10 | $58.75 |
| 52 Week High | $198.63 | $89.77 |
| Indicator | AVB | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 62.19 |
| Support Level | $174.68 | $69.17 |
| Resistance Level | $188.44 | $72.77 |
| Average True Range (ATR) | 3.36 | 1.94 |
| MACD | -0.54 | 0.77 |
| Stochastic Oscillator | 19.11 | 85.39 |
AvalonBay Communities owns a portfolio of 296 apartment communities with more than 90,000 units and is developing 24 additional properties with approximately 8,600 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).